Journalartikel
Autorenliste: Tarner, I. H.; Mueller-Ladner, U.; Hamm, C.
Jahr der Veröffentlichung: 2010
Seiten: 702-70+
Zeitschrift: Zeitschrift für Rheumatologie
Bandnummer: 69
Heftnummer: 8
ISSN: 0340-1855
eISSN: 1435-1250
DOI Link: https://doi.org/10.1007/s00393-009-0583-7
Verlag: Springer
Abstract:
Over the course of the last decade, biologic response modifiers (biologics) have significantly broadened the therapeutic armamentarium in clinical rheumatology. In addition to their impressive efficacy, they have also received considerable attention regarding their adverse effects. In contrast to the risk of severe infections and malignancies, the cardiovascular risk of these drugs has provoked less vigilance. This article reviews the current data on the cardiovascular effects and adverse effects of biologics.
Zitierstile
Harvard-Zitierstil: Tarner, I., Mueller-Ladner, U. and Hamm, C. (2010) Biologics and cardiovascular risk, Zeitschrift für Rheumatologie, 69(8), pp. 702-70+. https://doi.org/10.1007/s00393-009-0583-7
APA-Zitierstil: Tarner, I., Mueller-Ladner, U., & Hamm, C. (2010). Biologics and cardiovascular risk. Zeitschrift für Rheumatologie. 69(8), 702-70+. https://doi.org/10.1007/s00393-009-0583-7
Schlagwörter
ADVANCED HEART-FAILURE; ANTI-TNF THERAPY; Biologics; cardiovascular risk; Congestive heart failure; DOUBLE-BLIND; ETANERCEPT; FACTOR-ALPHA THERAPY; IMPROVES ENDOTHELIAL FUNCTION; INTERLEUKIN-6 RECEPTOR INHIBITION; RHEUMATOID-ARTHRITIS PATIENTS; TOCILIZUMAB
